Figure 3.

Conformation-selective inhibitors modulate SH2 domain accessibility. (A) SH2-binding peptide conjugated to resin. (B) Quantification of the SH2 pull-down assays performed with Src and Hck in the presence of various inhibitors (mean ± SEM, n = 3). The amount of kinase eluted from the beads is normalized to that of SFK–1.